HRP20221230T1 - Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu - Google Patents
Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu Download PDFInfo
- Publication number
- HRP20221230T1 HRP20221230T1 HRP20221230TT HRP20221230T HRP20221230T1 HR P20221230 T1 HRP20221230 T1 HR P20221230T1 HR P20221230T T HRP20221230T T HR P20221230TT HR P20221230 T HRP20221230 T HR P20221230T HR P20221230 T1 HRP20221230 T1 HR P20221230T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- pharmaceutical combination
- pharmaceutically acceptable
- bcl
- cancer
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title claims 7
- 229940123711 Bcl2 inhibitor Drugs 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 102000011427 Histone Deacetylase 6 Human genes 0.000 claims 6
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 2
- 229960001183 venetoclax Drugs 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Farmaceutska kombinacija koja sadrži:
(a) inhibitor histon deacetilaze 6 (HDAC6) formule I:
[image]
ili njegovu farmaceutski prihvatljivu sol,
u kojem,
prsten B je aril ili heteroaril;
R1 je aril ili heteroaril, od kojih svaki može biti izborno supstituiran sa OH, halo ili C1-6-alkil; i
R je H ili C1-6-alkil; i
(b) inhibitor BCL-2, gdje inhibitor BCL-2 je 2-((1H-pirolo[2,3-b]piridin-5-il)oksi)-4-(4((4'-kloro)-5,5-dimetil-3,4,5,6-tetrahidro-[1,1'-bifenil]-2-il)metil)piperazin-1-il)-N-((3nitro-4-(((tetrahidro-2H-piran-4-il)metil)amino)fenil)sulfonil)benzamid (venetoklaks) ili njegove farmaceutski prihvatljive soli.
2. Farmaceutska kombinacija prema zahtjevu 1, naznačena time što:
(a) spoj formule I je:
[image]
ili njegova farmaceutski prihvatljiva sol; ili gdje:
(b) spoj formule I je:
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Farmaceutska kombinacija prema zahtjevu 1 ili zahtjevu 2, naznačena time što inhibitor HDAC6 i inhibitor BCL-2 su:
(a) u istoj formulaciji; ili
(b) u odvojenim formulacijama.
4. Farmaceutska kombinacija prema zahtjevu 1 ili zahtjevu 2, naznačena time što je kombinacija za istovremenu ili sekvencijalnu primjenu.
5. Farmaceutska kombinacija prema zahtjevu 1 ili zahtjevu 2 za uporabu u liječenju raka kod subjekta kojem je to potrebno.
6. Farmaceutska kombinacija za uporabu prema zahtjevu 5, naznačena time što, rak je hematološki rak.
7. Farmaceutska kombinacija za uporabu prema zahtjevu 5, naznačena time što, rak je refraktoran ili otporan na tretman sa najmanje jednom prethodnom terapijom.
8. Terapeutski efikasna količina
(a) inhibitora histon deacetilaze 6 (HDAC6) formule I:
[image]
ili njegove farmaceutski prihvatljive soli,
u kojem,
prsten B je aril ili heteroaril;
R1 je aril ili heteroaril, od kojih svaki može biti izborno supstituiran sa OH, halo ili C1-6-alkil; i
R je H ili C1-6-alkil; i
(b) inhibitora BCL-2, gdje inhibitor BCL-2 je 2-((1H-pirolo[2,3-b]piridin-5-il)oksi)-4-(4((4'-kloro)-5,5-dimetil-3,4,5,6-tetrahidro-[1,1'-bifenil]-2-il)metil)piperazin-1-il)-N-((3nitro-4-(((tetrahidro-2H-piran-4-il)metil)amino)fenil)sulfonil)benzamid (venetoklaks) ili njegove farmaceutski prihvatljive soli,
za uporabu u liječenju ili prevenciji raka kod subjekta kojem je to potrebno.
9. Terapeutski efikasna količina za uporabu prema zahtjevu 8, naznačena time što:
(a) spoj formule I je:
[image]
ili njegova farmaceutski prihvatljiva sol; ili gdje:
(b) spoj formule I je:
[image]
ili njegova farmaceutski prihvatljiva sol.
10. Terapeutski efikasna količina za uporabu prema zahtjevu 8 ili zahtjevu 9, naznačena time što, rak je hematološki rak.
11. Terapeutski efikasna količina za uporabu prema bilo kojem od zahtjeva 8 do 10, naznačena time što, rak je refraktoran ili otporan na tretman sa najmanje jednom prethodnom terapijom.
12. Terapeutski efikasna količina za uporabu prema bilo kojem od zahtjeva 8 do 10, naznačena time što se inhibitor HDAC6 i inhibitor BCL-2 primjenjuju:
(a) približno u isto vrijeme; ili
(b) u različito vrijeme.
13. Farmaceutska kombinacija prema bilo kojem od zahtjeva 1-4 za uporabu u postupku za smanjenje rasta i održivosti stanice, naznačena time što postupak sadrži dovođenje u kontakt stanice sa farmaceutskom kombinacijom, i pri čemu, stanica je stanica leukemije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417670P | 2016-11-04 | 2016-11-04 | |
| EP17866600.4A EP3535275B1 (en) | 2016-11-04 | 2017-11-03 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a bcl-2 inhibitor and methods of use thereof |
| PCT/US2017/059927 WO2018085652A1 (en) | 2016-11-04 | 2017-11-03 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a bcl-2 inhibitor and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221230T1 true HRP20221230T1 (hr) | 2022-12-09 |
Family
ID=62076504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221230TT HRP20221230T1 (hr) | 2016-11-04 | 2017-11-03 | Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11666568B2 (hr) |
| EP (1) | EP3535275B1 (hr) |
| JP (2) | JP7535853B2 (hr) |
| DK (1) | DK3535275T3 (hr) |
| ES (1) | ES2925197T3 (hr) |
| HR (1) | HRP20221230T1 (hr) |
| HU (1) | HUE060208T2 (hr) |
| LT (1) | LT3535275T (hr) |
| PL (1) | PL3535275T3 (hr) |
| PT (1) | PT3535275T (hr) |
| RS (1) | RS63534B1 (hr) |
| SI (1) | SI3535275T1 (hr) |
| WO (1) | WO2018085652A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201803594A (zh) * | 2016-06-09 | 2018-02-01 | 達納-法伯癌症協會 | Hdac抑制劑與bet抑制劑之使用方法及醫藥組合 |
| WO2018098168A1 (en) | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| JP2024519499A (ja) | 2021-05-04 | 2024-05-14 | テナヤ セラピューティクス， インコーポレイテッド | 代謝疾患及びｈｆｐｅｆの治療に使用するための２－フルオロアルキル－１，３，４－オキサジアゾール－５－イル－チアゾール、ｈｄａｃ６阻害剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| WO2011091213A2 (en) * | 2010-01-22 | 2011-07-28 | Acetylon Pharmaceuticals | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| KR20160092018A (ko) | 2013-12-03 | 2016-08-03 | 에이스틸론 파마수티컬스 인코포레이티드 | 히스톤 탈아세틸화효소 저해제 및 면역조절 약물의 조합 |
| EP3139942B1 (en) * | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
-
2017
- 2017-11-03 US US16/344,873 patent/US11666568B2/en active Active
- 2017-11-03 SI SI201731224T patent/SI3535275T1/sl unknown
- 2017-11-03 HU HUE17866600A patent/HUE060208T2/hu unknown
- 2017-11-03 EP EP17866600.4A patent/EP3535275B1/en active Active
- 2017-11-03 PT PT178666004T patent/PT3535275T/pt unknown
- 2017-11-03 ES ES17866600T patent/ES2925197T3/es active Active
- 2017-11-03 PL PL17866600.4T patent/PL3535275T3/pl unknown
- 2017-11-03 WO PCT/US2017/059927 patent/WO2018085652A1/en unknown
- 2017-11-03 JP JP2019522675A patent/JP7535853B2/ja active Active
- 2017-11-03 LT LTEPPCT/US2017/059927T patent/LT3535275T/lt unknown
- 2017-11-03 DK DK17866600.4T patent/DK3535275T3/da active
- 2017-11-03 RS RS20220826A patent/RS63534B1/sr unknown
- 2017-11-03 HR HRP20221230TT patent/HRP20221230T1/hr unknown
-
2022
- 2022-10-13 JP JP2022164832A patent/JP2022188265A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7535853B2 (ja) | 2024-08-19 |
| US11666568B2 (en) | 2023-06-06 |
| WO2018085652A1 (en) | 2018-05-11 |
| PL3535275T3 (pl) | 2022-10-24 |
| DK3535275T3 (da) | 2022-09-12 |
| US20190262337A1 (en) | 2019-08-29 |
| ES2925197T3 (es) | 2022-10-14 |
| EP3535275A4 (en) | 2020-06-24 |
| LT3535275T (lt) | 2022-09-26 |
| SI3535275T1 (sl) | 2022-10-28 |
| EP3535275A1 (en) | 2019-09-11 |
| PT3535275T (pt) | 2022-08-26 |
| RS63534B1 (sr) | 2022-09-30 |
| JP2019537580A (ja) | 2019-12-26 |
| EP3535275B1 (en) | 2022-07-13 |
| JP2022188265A (ja) | 2022-12-20 |
| HUE060208T2 (hu) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221230T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu | |
| TWI672150B (zh) | 抗生素藥物臨床新應用 | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| HRP20170627T1 (hr) | Derivati 2-metilmorfolin pirido-, pirazo- i pirimido-pirimidina kao inhibitori mtor | |
| EP1592665A4 (en) | HISTONE DEACETYLASE INHIBITORS OF NEW POWERFUL DIFFERENTIATION BENZAMIDE DERIVATIVES WITH PROLIFERATION-INHIBITING ACTIVITY | |
| HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| IN2014MN01754A (hr) | ||
| AR087545A1 (es) | 1h-imidazo[4,5-c]quinolina sustituidos con actividad inhibitoria de bromodominio | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| BR112013012740A2 (pt) | sais e formas cristalinas de um agente que induz apoptose | |
| RU2017134002A (ru) | Стабильные композиции тетрагидробиоптерина | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112014015845A8 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
| HRP20171824T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A | |
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| RU2014107484A (ru) | ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2 | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| JP2014517001A5 (hr) | ||
| PE20081578A1 (es) | Formulacion en polvo de valganciclovir | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| BRPI0519057A2 (pt) | derivados de hidantoÍna éteis como inibidores de metaloproteinase |